Get a proposal

Rare & Genetic · Clinical trials

Haemophilia B Clinical Trials

Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.

Indication overview

About haemophilia b — and why its trials are hard

Haemophilia B, also called Christmas disease, is an X-linked recessive bleeding disorder caused by deficiency or dysfunction of coagulation factor IX. Like haemophilia A, severity is defined by residual factor activity and manifests as spontaneous joint and soft-tissue bleeding, with the risk of chronic arthropathy. Historical management uses intravenous factor IX replacement, plasma-derived or recombinant, given on-demand or as prophylaxis; extended half-life factor IX products (including fusion and pegylated molecules) allow less frequent infusions. Inhibitor formation is less common than in haemophilia A but can occur. The field has advanced with AAV-based gene therapies delivering a factor IX transgene—often the hyperactive Padua variant—to enable durable endogenous factor IX production from a single infusion. Etranacogene dezaparvovec (Hemgenix) and fidanacogene elaparvovec (Beqvez) are the approved one-time gene therapies. Non-factor rebalancing agents that lower natural anticoagulants are also expanding options across haemophilia A and B. The annualised bleeding rate (ABR) remains the pivotal efficacy endpoint, alongside factor IX activity and reduced infusion requirements.

Indication
Haemophilia B
ICD-10-CM
D67 — Hereditary factor IX deficiency

Approved therapies & pivotal evidence

What's been approved — and by how much it moved the endpoint

Drug (brand)ApprovedSettingPivotal trialPrimary endpointMagnitude of benefit
Etranacogene dezaparvovec (Hemgenix)2022One-time gene therapy for adults with haemophilia B on prophylaxis or with severe/recurrent bleedingHOPE-B (phase 3, NEJM)Annualised bleeding rate after gene therapy vs lead-in factor IX prophylaxis (non-inferiority/superiority)~64% reduction in ABR vs lead-in period; most patients stopped routine factor IX prophylaxis
Fidanacogene elaparvovec (Beqvez)2024One-time gene therapy for adults with moderately severe to severe haemophilia B (AAV-negative)BENEGENE-2 (phase 3)Annualised bleeding rate after infusion vs prior factor IX prophylaxis (non-inferiority)Met non-inferiority with reduced ABR vs the prophylaxis lead-in period; durable FIX expression

Where trials have failed

Drugs that missed their endpoint — and what contributed

The most instructive lessons in haemophilia b development come from programmes that failed the endpoint that mattered.

Drug / trialEndpoint outcomeWhat contributed
BAX 335 (fidanacogene predecessor, Baxalta AAV8-FIX Padua) — Phase 1/2 haemophilia B gene therapyDid not advance; factor IX expression declined over time in some participantsAAV capsid-directed immune responses/transaminitis and waning transgene expression; the program was not continued to registration in this form

Choosing the right endpoint

Primary endpoints that matter in haemophilia b trials

  • Annualised bleeding rate (ABR) — Primary efficacy endpoint; often compared against a factor IX prophylaxis lead-in period in gene-therapy trials
  • Factor IX activity — Circulating FIX level after treatment; central pharmacodynamic measure of gene-therapy expression and durability
  • Factor IX consumption — Reduction or cessation of exogenous factor IX infusions following gene therapy
  • AAV neutralising antibodies — Pre-existing anti-AAV immunity affects eligibility and response to AAV gene therapies

How iNGENū runs haemophilia b trials

Physician-led design, built for FDA submission

Endpoint & biomarker strategy

Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.

FDA-ready data

Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.

Faster, lower-cost delivery

~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.

Planning a haemophilia b trial?
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Request a proposal

Frequently asked questions

Haemophilia B clinical trials — FAQs

What is the difference between haemophilia A and B?
Both are X-linked bleeding disorders with similar symptoms, but haemophilia A is caused by factor VIII deficiency and haemophilia B by factor IX deficiency. They require different replacement factors and different gene therapies.
How do haemophilia B gene therapies work?
They use an adeno-associated virus vector to deliver a factor IX gene—frequently the high-activity Padua variant—to the liver, enabling patients to produce their own factor IX after a single infusion and reducing or eliminating regular prophylaxis.
Who is eligible for gene therapy?
Eligibility generally requires adults with moderately severe to severe haemophilia B, absence of factor IX inhibitors, and low or absent pre-existing neutralising antibodies to the AAV vector; liver health is also assessed.

Ready to discuss your haemophilia b trial?

Talk to our physician-led team about an FDA-ready, cost-efficient trial design.

Request a proposal